Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Chinese Drugmaker to Expand Production of Polysaccharides and Enzyme Drugs

By Changzhou National Hi-Tech District | December 5, 2018

Changzhou Qianhong Bio-pharma Co., Ltd., a leading biochemical maker of polysaccharides and enzyme drugs, has started construction on phase two of its pharmaceuticals production facility at Changzhou National Hi-Tech District.

With an investment of 1 billion yuan ($146 million), the phase two project adds 200 million tablets and 60 million injections to production as well as making molecular diagnosis reagents available for use by 20 million people.

The company is a major manufacturer of pancreatic kininogenase, heparin sodium, and low molecular weight heparin, as well as compound digestive enzyme preparations and asparaginase, all of which had, prior to the roll out of its phase one facility, never been produced in China.

Several products have been granted quality certifications by governing bodies in the U.S., the EU, and Japan. The company has set up an international marketing network, with products being sold in more than 20 provinces and cities across China as well as exported to markets abroad. 

The phase two development will focus on the research and development of innovative and first-of-its-class-in-China biological drugs with its own intellectual property rights, and with the aim of treating patients with critical illnesses, including cancer, cardiovascular, and cerebrovascular diseases.

(Source: Changzhou National Hi-Tech District via PR Newswire)

Related Articles Read More >

This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE